Integra LifeSciences Holdings (NASDAQ:IART) First Quarter 2025 Results

Key Financial Results

Revenue: US$382.7m (up 3.7% from 1Q 2024). Net loss: US$25.3m (loss widened by US$22.0m from 1Q 2024). US$0.33 loss per share (further deteriorated from US$0.042 loss in 1Q 2024).

Our free stock report includes 1 warning sign investors should be aware of before investing in Integra LifeSciences Holdings. Read for free now.NasdaqGS:IART Earnings and Revenue Growth May 6th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Integra LifeSciences Holdings EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly.

Looking ahead, revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are down 20% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Integra LifeSciences Holdings has  1 warning sign  we think you should be aware of.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments